一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> Oncogene >>article
Oncogene

Oncogene

IF: 7.3
Download PDF

CRL2KLHDC3 mediates p14ARF N-terminal ubiquitylation degradation to promote non-small cell lung carcinoma progression

Published:25 April 2022 DOI: 10.1038/s41388-022-02318-6
Yang Liu, Yuewen Luo, Shumei Yan, Yi-Fan Lian, Shiyu Wu, Miao Xu, Lin Feng, Xu Zhang, Rong Li, Xiantao Zhang, Qi-Sheng Feng, Yi-Xin Zeng, Hui Zhang

Abstract

Kelch superfamily involves a variety of proteins containing multiple kelch motif and is well characterized as substrate adaptors for CUL3 E3 ligases, which play critical roles in carcinogenesis. However, the role of kelch proteins in lung cancer remains largely unknown. In this study, the non-small cell lung cancer (NSCLC) patients with higher expression of a kelch protein, kelch domain containing 3 (KLHDC3), showed worse overall survival. KLHDC3 deficiency affected NSCLC cell lines proliferation in vitro and in vivo. Further study indicated that KLHDC3 mediated CUL2 E3 ligase and tumor suppressor p14ARF interaction, facilitating the N-terminal ubiquitylation and subsequent degradation of p14ARF. Interestingly, Gefitinib-resistant NSCLC cell lines displayed higher KLHDC3 protein levels. Gefitinib and Osimertinib medications were capable of upregulating KLHDC3 expression to promote p14ARF degradation in the NSCLC cell lines. KLHDC3 shortage significantly increased the sensitivity of lung cancer cells to epidermal growth factor receptor (EGFR)-targeted drugs, providing an alternative explanation for the development of Gefitinib and Osimertinib resistance in NSCLC therapy. Our works suggest that CRL2KLHDC3 could be a valuable target to regulate the abundance of p14ARF and postpone the occurrence of EGFR-targeted drugs resistance.

Substances (8)

Materials
Procduct Name CAS Molecular Formula Supplier Price
Gefitinib 184475-35-2 C22H24ClFN4O3 811 suppliers $5.00-$1141.00
Gefitinib 184475-35-2 C22H24ClFN4O3 811 suppliers $5.00-$1141.00
Gefitinib 184475-35-2 C22H24ClFN4O3 811 suppliers $5.00-$1141.00
Gefitinib 184475-35-2 C22H24ClFN4O3 811 suppliers $5.00-$1141.00
Gefitinib 184475-35-2 - Inquiry
Gefitinib 184475-35-2 - Inquiry
Gefitinib 184475-35-2 C22H24ClFN4O3 - Inquiry
Gefitinib 184475-35-2 C22H24ClFN4O3 - Inquiry

Similar articles

IF:9.6

EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins

Cancer treatment reviews Jordi Remon , Lizza E.L. Hendriks ,etc Published: 1 November 2020
IF:3

A comprehensive review on Brigatinib – A wonder drug for targeted cancer therapy in non-small cell lung cancer

Saudi Pharmaceutical Journal Silky Bedi , Shah A. Khan ,etc Published: 1 September 2018
岳阳县| 嘉定区| 胶南市| 唐山市| 荣成市| 北流市| 开平市| 安达市| 泰来县| 密云县| 芦山县| 浦江县| 阿瓦提县| 灌云县| 临洮县| 龙川县| 柳林县| 阳高县| 修武县| 喀喇| 桃园县| 碌曲县| 敦化市| 延安市| 五家渠市| 泰安市| 邻水| 搜索| 濉溪县| 静宁县| 武鸣县| 永康市| 页游| 化德县| 岗巴县| 日土县| 商丘市| 丰城市| 鄄城县| 尚志市| 建水县|